Skip to main content
DR REDDYS LABORATORIES LTD logo

DR REDDYS LABORATORIES LTD — Investor Relations & Filings

Ticker · RDY ISIN · US2561352038 LEI · 335800OVDPY3DVZR2798 BSE.NS Manufacturing
Open in API
Filings indexed 2,323 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country IN India
Listing BSE.NS RDY

About DR REDDYS LABORATORIES LTD

https://www.drreddys.com/

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company focused on providing affordable and innovative medicines. The company's core activities include the development, manufacturing, and marketing of a broad portfolio of products. This portfolio encompasses Active Pharmaceutical Ingredients (APIs), generic and branded-generic formulations, over-the-counter (OTC) products, and biologics. In addition to its significant presence in the generics market, the company invests in the research and development of novel molecules and proprietary products, with a focus on therapeutic areas such as dermatology and neurology. Dr. Reddy's is also committed to sustainable operations, actively working to reduce its environmental footprint through initiatives in water conservation, waste reduction, and decarbonisation.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings
2026-05-28 English
Annual Secretarial Compliance certificate for the year ended March 31, 2026
Regulatory Filings Classification · 87% confidence The document is an Annual Secretarial Compliance Report under SEBI Listing Regulations, prepared and signed by the Company Secretary and a Practicing Company Secretary. It is an attestation/certification of compliance rather than a substantive financial report or corporate filing like an annual report, interim report, or proxy statement. Under the Certification Rule, officer attestations are classified as Regulatory Filings (RNS).
2026-05-28 English
Press Release
Regulatory Filings Classification · 85% confidence The document is a press release submitted under SEBI Regulation 30 to stock exchanges, announcing an event (NYSE Closing Bell ceremony). It contains no financial statements, proxy materials, management discussion, or other report attachments. It is a general regulatory announcement in compliance with listing disclosure requirements, fitting the Regulatory Filings (RNS) category.
2026-05-28 English
Disclosure under Regulation 30 of SEBI (LODR) 2015, regarding Press release viz. "Dr. Reddy''s Laboratories to Ring the Closing Bell at New York Stock Exchange."
Regulatory Filings Classification · 72% confidence The document is a corporate press release submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. It announces a ceremonial event (ringing the NYSE closing bell) rather than presenting financial results, a meeting proxy, an audit opinion, or other regulatory report. It does not fit into specific categories like earnings release, board changes, or dividend notice. Therefore it falls under miscellaneous regulatory announcements (Regulatory Filings).
2026-05-28 English
FORM 6-K
Regulatory Filings
2026-05-28 English
Copy of Newspaper Publication
Regulatory Filings Classification · 15% confidence The document is a letter from Dr. Reddy’s Laboratories to the stock exchanges enclosing a copy of a newspaper notice concerning the transfer of unclaimed dividends and underlying equity shares to the Investor Education and Protection Fund (IEPF). It is not an actual financial report or dividend payment notice but a general regulatory announcement to the exchanges, falling under miscellaneous regulatory filings. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.